

D1
D1
1. (Three Times Amended) A post-gastrically available delayed release oral (DRO) pharmaceutical composition for the treatment or prophylaxis of inflammatory bowel disease (IBD), said composition comprising as the sole therapeutically active ingredient a polysaccharide selected from the group consisting of xanthan gum and hydroxypropylmethylcellulose (HPMC) in an amount effective to treat inflammatory bowel disease, together with a pharmaceutically acceptable carrier or vehicle.

D2
D2
22. (Three Times Amended) A method for the treatment or prophylaxis of inflammatory bowel disease (IBD) comprising contacting the diseased mucosa of the gastro-intestinal tract with a therapeutic amount of a polysaccharide selected from the group consisting of xanthan gum and hydroxypropylmethyl-cellulose (HPMC) as the sole therapeutic agent

D3
33. (Amended) A rectally administrable pharmaceutical composition for the treatment or prophylaxis of inflammatory bowel disease (IBD), said composition comprising hydroxypropylmethylcellulose (HPMC) as the sole therapeutically active agent in an amount effective to treat inflammatory bowel disease, together with a pharmaceutically acceptable carrier or vehicle.